UCB SA (OTCMKTS:UCBJY – Get Free Report)’s share price reached a new 52-week high on Wednesday . The company traded as high as $100.43 and last traded at $100.18, with a volume of 7440 shares traded. The stock had previously closed at $98.57.
UCB Stock Performance
The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The stock’s 50 day simple moving average is $96.66 and its 200 day simple moving average is $90.00.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- How to Calculate Options Profits
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- How to Calculate Stock Profit
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- What is the NASDAQ Stock Exchange?
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
